Table 1 Clinico-pathological characteristics of 120 bladder cancer patients.
From: The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
| Â | No. of patients | p value | |
|---|---|---|---|
PD-L1 (−) | PD-L1 (+) | ||
Age | Â | Â | 0.415 |
 Median | 71 | 73.1 |  |
 Range | 45.5–91.5 | 46.5–90 |  |
Gender | Â | Â | 0.39 |
 Male | 49 (79%) | 42 (72%) |  |
 Female | 13 (21%) | 16 (28%) |  |
T-stage | Â | Â | 0.0003* |
 T1 | 22 (35%) | 6 (10.3%) |  |
 T2 | 31 (50%) | 28 (48.3%) |  |
 T3-T4 | 9 (15%) | 24 (41.4%) |  |
Pathologic grade | Â | Â | 0.83 |
 Low-intermediate | 33 (53%) | 32 (55%) |  |
 High | 29 (47%) | 26 (45%) |  |
LN involvement | Â | Â | 0.013* |
 Negative | 51 (82%) | 36 (62%) |  |
 Positive | 11 (18%) | 22 (38%) |  |
Distant metastasis | Â | Â | 0.14 |
 Negative | 56 (90%) | 47 (81%) |  |
 Positive | 6 (10%) | 11 (19%) |  |
Loco-regional failure | |||
 Negative | 55 (89%) | 25 (43%) | 0.000* |
 Positive | 7 (11%) | 33 (57%) |  |
